N1,N2-bis(3-chlorobenzyl)ethane-1,2-diamine | 108896-77-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N1,N2-bis(3-chlorobenzyl)ethane-1,2-diamine
• 英文别名: N,N'-bis(3-chlorobenzyl)ethylenediamine；N~1~,N~2~-bis(3-chlorobenzyl)-1,2-ethanediamine；N,N'-bis[(3-chlorophenyl)methyl]ethane-1,2-diamine
• CAS: 108896-77-1
• 化学式: C₁₆H₁₈Cl₂N₂
• 分子量: 309.238
• InChiKey: WCBIPPOEAIYUNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N1,N2-bis(3-chlorobenzyl)ethane-1,2-diamine 在 劳森试剂 作用下， 以 甲苯 、 xylene 为溶剂， 反应 5.0h， 生成 1,5-Bis[(3-chlorophenyl)methyl]-1,3,5-triazepane-2,4-dithione
  参考文献：
  名称：

  Sawanishi; Wakusawa; Murakami, Journal of Medicinal Chemistry, 1995, vol. 38, # 26, p. 5066 - 5070

  摘要：

  DOI：
• 作为产物：
  描述：

  N1,N2-bis(3-chlorobenzylidene)ethane-1,2-diamine 在 sodium tetrahydroborate 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.0h， 以75%的产率得到N1,N2-bis(3-chlorobenzyl)ethane-1,2-diamine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Substituted-Imidazolidine Derivatives

  摘要：

  研究人员合成了一系列较新的取代咪唑烷衍生物 3a-k，并对其进行了体内试验，以研究它们的抗炎、镇痛和抗溃疡活性。生物学评价结果表明，4-[1,3-双（4-羟基-3-甲氧基苄基）-2-咪唑烷基]苯二乙胺（3g）、4-[1、3-双（3-乙氧基-4-羟基苄基）-2-咪唑烷基]苯基二乙胺（3h）和 4-（1,3-双（苯并[d][1,3]二恶茂-5-基甲基）-4-甲基咪唑烷-2-基）-N,N-二乙基苯胺（3j）具有良好的抗炎和镇痛作用。此外，与标准药物相比，这些衍生物在低严重指数方面显示出更优越的胃肠道安全性。这些结果经统计学处理，具有重要意义。

  DOI：

  10.5012/jkcs.2013.57.2.227

文献信息

• Multidrug resistance inhibitors
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0781552A1

  公开（公告）日：1997-07-02

  There is disclosed a multidrug resistance inhibitor for overcoming a multidrug resistance of cancer, or an agent for enhancing the activity of anti-cancer agents, which comprises as an active ingredient a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein n is an integer of 5 to 12, R1 and R2 are each independently benzyl, of which a phenyl ring may be substituted by 1 to 5 substituents selected from hydroxy, (C1-C4)alkyl, (C1-C4)alkoxy and halogen, and/or by methylenedioxy, with the proviso that R1 and R2 are simultaneously not a compound of formula (II)

  本发明公开了一种用于克服癌症多药耐药性的多药耐药性抑制剂，或一种用于增强抗癌剂活性的制剂，其活性成分包括式（I）化合物或其药学上可接受的盐： 其中 n 是 5 至 12 的整数、 R1 和 R2 各自独立地为苄基，其中一个苯基环可被 1 至 5 个选自羟基、(C1-C4)烷基、(C1-C4)烷氧基和卤素的取代基取代，和/或被亚甲基二氧基取代，但 R1 和 R2 同时不是式（II）化合物
• Imidazolidines as new anti-Trypanosoma cruzi agents: Biological evaluation and structure–activity relationships
  作者：M. Cristina Caterina、Isabel A. Perillo、Lucía Boiani、Horacio Pezaroglo、Hugo Cerecetto、Mercedes González、Alejandra Salerno

  DOI：10.1016/j.bmc.2007.11.077

  日期：2008.3

  Imidazolidine derivatives were studied as anti-Trypanosoma cruzi agents. Imidazolines can be considered as ethylenediamine/carbonyl precursors and therefore interfere with the biosynthesis of polyamines into the parasite. Some of the derivatives were found to have high and selective activity against the proliferative stages of the parasite, with IC50 values against the epimastigote form in the low micromolar range as the reference drug Nifurtimox. The imidazolidines demonstrated to be stable after five days of incubation in buffer glucose, pH 7, indicating that diamines were not obtained in these conditions. But it was found that two of the studied diamine precursors were as active as the parent compounds. Probably, the imidazolidines affect the mitochondrial integrity according to the excreted end-products found in the NMR studies. The QSAR studies indicated that the bioactivities are correlated with the lipophilicities. In conclusion, we have described a new and relevant bioactivity for imidazolidines. The results support further in vivo studies of some of these imidazolidine derivatives. (C) 2007 Elsevier Ltd. All rights reserved.
• US6011069A
  申请人：——

  公开号：US6011069A

  公开（公告）日：2000-01-04